Public Comment: Opposition to Fast Track Licensure of MF59 Adjuvanted Fluad

Squalene adjuvants hyper-stimulate the immune system and have been linked with development of autoimmunity, narcolepsy and other chronic disease.1 2 3 Based on the very limited safety and immunogenicity evidence submitted by Novartis,4 MF59 adjuvanted Fluad vaccine should not be fast tracked to licensure for use by seniors over age 65 in the U.S. for the following reasons:

Read full story here: Public Comment: Opposition to Fast Track Licensure of MF59 Adjuvanted Fluad

Please follow and like us:

Related Post

Leave a Reply